PSA Glycomics Assay for Early Detection of Prostate Cancer

Last updated: September 22, 2023
Sponsor: Prof.dr. H.P. Beerlage
Overall Status: Active - Recruiting

Phase

N/A

Condition

Prostate Cancer, Early, Recurrent

Urologic Cancer

Prostate Disorders

Treatment

PSA Glycomics Assay

Clinical Study ID

NCT04393376
NL73261.018.20
  • Ages > 18
  • Male
  • Accepts Healthy Volunteers

Study Summary

The principal aim of this pilot study is to test whether the PSA Glycomics Assay on urine and serum samples can provide insights regarding the disease state of patients with elevated PSA concentrations, as well as to accurately identify if the patient has prostate cancer and, in the case of prostate cancer, to determine its level of aggressiveness.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • Patients with elevated PSA (>3 ng/mL)
  • Signed informed consent

Exclusion

Exclusion Criteria:

  • Patients that have a cystitis (bladder infection)
  • Patients under chemotherapy
  • Patients using 5-alpha reductase inhibitors
  • History or presence of cancers, or non-prostate urological disorders.

Study Design

Total Participants: 150
Treatment Group(s): 1
Primary Treatment: PSA Glycomics Assay
Phase:
Study Start date:
August 01, 2020
Estimated Completion Date:
August 01, 2025

Connect with a study center

  • Amsterdam UMC, location AMC

    Amsterdam, Noord Holland 1105 AZ
    Netherlands

    Completed

  • Amsterdam UMC, location VUmc

    Amsterdam,
    Netherlands

    Active - Recruiting

  • Leiden University Medical Centre

    Leiden,
    Netherlands

    Active - Recruiting

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.